(Q39207741)

10 September 2017

Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies (English)

1 reference

10 September 2017

17

1 reference

10 September 2017

R Natrajan

4

0 references

Alan Ashworth

18

object named as

A Ashworth

1 reference

10 September 2017

3

A Mackay

1 reference

10 September 2017

K-K Shiu

1

1 reference

10 September 2017

D Wetterskog

2

1 reference

10 September 2017

M Lambros

5

1 reference

10 September 2017

D Sims

6

1 reference

10 September 2017

I Bajrami

7

1 reference

10 September 2017

R Brough

8

1 reference

10 September 2017

J Frankum

9

1 reference

10 September 2017

R Sharpe

10

1 reference

10 September 2017

C Marchio

11

1 reference

10 September 2017

H Horlings

12

1 reference

10 September 2017

F Reyal

13

1 reference

10 September 2017

M van der Vijver

14

1 reference

10 September 2017

N Turner

15

1 reference

10 September 2017

J S Reis-Filho

16

1 reference

10 September 2017

language of work or name

English

0 references

publication date

21 January 2013

1 reference

10 September 2017

1 reference

10 September 2017

33

1 reference

10 September 2017

5

1 reference

10 September 2017

619-631

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2012.625

10 September 2017

0 references

cites work

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

DNA amplifications in breast cancer: genotypic-phenotypic correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Tiling path genomic profiling of grade 3 invasive ductal breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Novel patterns of genome rearrangement and their association with survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

ROCK: a breast cancer functional genomics resource.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Genome profiling of ERBB2-amplified breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Comparative genomic hybridisation arrays: high-throughput tools to determine targeted therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

A census of amplified and overexpressed human cancer genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Analysis of cell-based RNAi screens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Identification of target genes of transcription factor activator protein 2 gamma in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Wwox and Ap2gamma expression levels predict tamoxifen response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

The genomic profile of HER2-amplified breast cancers: the influence of ER status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Functional viability profiles of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.625

31 March 2020

Identifiers

DOI

10.1038/ONC.2012.625

1 reference

Dimensions Publication ID

10 September 2017

1012404890

0 references

Fatcat ID

release_6o2xzhuderc57bhyrtnwvv4n7m

0 references

1 reference